Record Revenue Growth
Total revenue grew 50.8% year-over-year to $28.0 million, above the high end of guidance ($27.0 - $27.5M). Full-year revenue guidance is $106.5M-$110.5M (30%-35% YoY growth).
Strong Profitability & Operating Leverage
Net income increased 110% to $5.4 million ($0.09 per diluted share). Operating margin expanded ~1,040 basis points to 23.8% (from 13.4%), and adjusted EBITDA increased 113.4% to $10.6 million with adjusted EBITDA margin up to 37.8% (from 26.7%).
Patient Affordability (Pharma) Momentum
Pharma/patient affordability revenue rose 81.9% to $15.7 million; claim volume ~49% higher than Q1 2025. Patient affordability deployed >$540 million in financial assistance in Q1 vs ~$320 million a year ago. Active pharma programs grew (exited quarter at 135, 141 active at call, expected 147-150 by quarter end).
Plasma Business Growth and Cash Generation
Plasma revenue increased 24.9% year-over-year to $11.7 million. Average monthly revenue per center rose to $6,671 from $6,517. Exited quarter with 573 centers (up 89 year-over-year) and the plasma business remains a strong source of cash; unrestricted cash $20.5M and no bank debt.
Gross Margin Expansion
Gross profit margin expanded to 65% from 62.9% YoY, reflecting a higher mix of higher-margin Pharma revenue.
Efficient Expense Growth
Cost of revenues increased 42.2% and total operating expenses rose 25.5% (to $11.6M), both growing well below revenue growth, demonstrating operating leverage.
Robust Pipeline & Business Development
Management reported a strong pipeline after Assembia (ASX 26) with >50 meetings and real-time deal wins; they expect to exceed the 55 net program adds achieved in 2025, with roughly a 50/50 split between new clients and expansions.
Conservative Balance Sheet & Customer Deposits
Restricted cash increased to $159M (primarily customer program deposits and funds on card), and management holds substantial cash for potential acquisitions, shareholder returns, or other uses; remaining acquisition cash obligation is ~$6M to Gamma over next three anniversaries.